文献速递脑血管病外科神经重症

体积分期立体定向放射外科治疗脑动静脉畸形的结局评估

Outcome Evaluation of Volume-Staged Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations.
PubMed 文献 · Neurosurgery · 2025-08-11

这项多中心回顾性队列纳入21个中心378例大型脑动静脉畸形(AVM)患者,评估体积分期立体定向放射外科(VS-SRS)治疗整个畸形团的结局。中位随访48-55个月,20.4%获良好结局,33.6%达闭塞,潜伏期出血发生率为3.02例/100患者年,19%出现症状性放射不良反应。

要点

  • VS-SRS可作为大型AVM的独立治疗方式,但闭塞率和良好结局率低于小型AVM。
  • VS-SRS后常需重复治疗,优化方案可提高处方剂量、减少每期体积并增加分期数。
  • 潜伏期出血发生率为3.02例/100患者年,19%出现症状性放射不良反应。

核心结论

  • VS-SRS可用于治疗大型AVM作为独立治疗,但闭塞率和良好结局率低于小型AVM,且常需重复治疗。

研究设计与样本

  • 多中心回顾性队列研究,纳入21个中心378例接受VS-SRS治疗整个AVM畸形团的患者。

主要发现

  • 127例(33.6%)达闭塞,3年和5年闭塞率分别为6.8%和26%;AVM<15 cm³的闭塞率分别为81%和31%。
  • 潜伏期出血发生率为3.02例/100患者年,52例(13.8%)发生出血。
  • 总畸形团体积、第一期处方剂量、弥漫性畸形团和既往出血均为结局率的独立影响因素。

临床怎么用

  • VS-SRS可作为大型AVM的独立治疗选择,但需告知患者闭塞率和良好结局率较低且常需重复治疗。
  • 优化治疗方案(提高处方剂量、减少每期治疗体积、增加分期数)可能改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Single-session stereotactic radiosurgery (SRS) has limited role for large arteriovenous malformations (AVM). Volume-staged SRS (VS-SRS) is used to optimize outcomes, but studies reporting results are limited. METHODS: This multicenter retrospective cohort of 378 patients from 21 centers reports results of VS-SRS for the entire AVM nidus. We report favorable outcome, obliteration, hemorrhage, and permanent symptomatic adverse radiation effect rates. RESULTS: The median age was 31 years (IQR: 19-44) at the first volume stage, with patients treated in 2-4 stages. The median total nidus volume was 21 cm 3 (IQR: 13.9-30.1 cm 3 ), and a median prescription dose of 17 Gy (IQR: 16-18 Gy) was used. The median radiographic and clinical follow-up were 48 and 55 months, respectively. Seventy-seven patients (20.4%) had a favorable outcome, with the 3-year and 5-year rates being 3.9% and 18%, respectively. 127 patients (33.6%) achieved obliteration, with the 3-year and 5-year rates being 6.8% and 26%, respectively. Obliteration rates of AVMs <15 cm 3 were 81% and 31%, respectively. The latency period hemorrhage incidence rate was 3.02 cases per 100 patient-years; 52 patients (13.8%) had a bleed. Seventy-two patients (19%) had symptomatic adverse radiation effect; in 38 patients (10.1%), these were permanent. Total nidus volume, prescription dose at first stage, diffuse nidus, and prior hemorrhage were all independent affecting outcome rates. CONCLUSION: VS-SRS can be used to treat large AVMs as a standalone treatment. Obliteration rates and favorable outcomes are lower than that with smaller AVMs, and repeat treatment is often required. Optimizing treatment plans, by increasing prescription doses, reducing treatment volume at each stage, and increasing the number of stages, may lead to better outcomes.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Mantziaris G, Hajikarimloo B, Tos SM, et al. Outcome Evaluation of Volume-Staged Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations. Neurosurgery. 2025. PMID: 40788018. doi:10.1227/neu.0000000000003682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。